Clinical trial · no report yet · Phase 3
ALASCCA
Adjuvant Low Dose Aspirin in Colorectal Cancer
- NCT02647099 ↗
- Active not recruiting
- Anna Martling
- 51 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 31 | |
| YouTube | 14 | |
| Podcasts | 6 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Double-blind Placebo-controlled Study With ASA Treatment in Colorectal Cancer Patients With Mutations in the PI3K Signaling Pathway
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Acetylsalicylic acid; Placebo
- Arms
- Aspirin · Active comparator
- Placebo · Placebo comparator
- Enrollment
- 626
- Primary outcomes
- Time To Recurrence (TTR)
- Sponsor
- Anna Martling with Uppsala University Hospital, Skane University Hospital
- Start
- Apr 7, 2016
- Primary completion
- Aug 2024
- Results posted
- Yes
- Registry record
- NCT02647099 · updated Mar 13, 2026
Publications
linked from the registry- Martling A, Hed Myrberg I, Nilbert M, Gronberg H, Granath F, Eklund M, Oresland T, Iversen LH, Haapamaki C, Janson M, Westberg K, Segelman J, Ersson U, Prytz M, Angenete E, Bergstrom R, Mayrhofer M, Glimelius B, Lindberg J; ALASCCA Study Group. Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. N Engl J Med. 2025 Sep 18;393(11):1051-1064. doi: 10.1056/NEJMoa2504650. PubMed 40961426